Title
Ginkgo biloba as an alternative medicine in the treatment of anxiety in dementia and other psychiatric disorders
Date Issued
01 April 2017
Access level
metadata only access
Resource Type
review
Author(s)
Singh S.K.
Aliev G.
Echeverria V.
Universidad Javeriana
Publisher(s)
Bentham Science Publishers B.V.
Abstract
Background: Mental disorders are the most common health problems in the worldwide population. Current medicines against these conditions have undesired side effects or limited effectiveness. These disadvantageous pharmacological and therapeutic characteristics provoke a low adherence to treatment in an important percentage of patients with mental disorders. Since ancient times, ethnically different groups have been using plants extracts as medicines for the treatment of mental conditions including dementia, depression and anxiety disorders. Among them are extracts of Ginkgo biloba, a tree in the division Gingophyta, that has been used by millions of people worldwide. Objective: This review aims to discuss current scientific evidence of efficacy, neuroprotective and antioxidant effects as mechanism of action, side effects and potential interaction with other commonly prescribed anxiolytic drugs. Methods: A PubMed search of preclinical studies as well as individual clinical trials and meta-analysis were scrutinized. Results: Various preclinical and clinical studies have shown a positive effect of Ginkgo biloba to improve cognitive abilities in impaired individuals and reducing anxiety under pathological conditions. Conclusion: A more advanced clinical research is needed to confirm the efficacy of Gingko biloba for the treatment of anxiety in different health conditions.
Start page
112
End page
119
Volume
18
Issue
2
Language
English
OCDE Knowledge area
Neurología clínica Ciencias de las plantas, Botánica Psiquiatría
Scopus EID
2-s2.0-85017419641
PubMed ID
Source
Current Drug Metabolism
ISSN of the container
13892002
Sponsor(s)
Funding text Drs. Valentina Echeverria, Gjumrakch Aliev, George E. Barreto and Sandeep Kumar Singh have no actual or potential conflict of interests concerning the topic in the present review. This work was financed with a Grant Fondecyt regular 1150194 (To VE). This work was performed with resources from the University San Sebastián, Chile and the Grant Fondecyt regular 1150194 (to VE). GEB work is supported by the Pontificia Universidad Javeriana and the Universidad Autónoma de Chile. G. Aliev work was supported by the Russian Science Foundation (www.rscf.ru, Grant No. 14-23-00160 for 2014-2016: Directed design, synthesis, and study of biological activity of multi-target compounds as innovative drugs for treatment of neurodegenerative diseases).
Sources of information: Directorio de Producción Científica Scopus